Nurix Therapeutics Announces Upcoming Webcast on Clinical Trial Data

Author: Caleb Price Updated: 06-06-2025 07:16 AM

Nurix Therapeutics Hosts Webcast to Discuss Trial Data

SAN FRANCISCO — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical organization dedicated to pioneering targeted protein degradation therapies, has exciting news to share. The company will be hosting a live webcast conference call to unveil significant findings from its ongoing Phase 1 clinical trial of bexobrutideg (NX-5948). This event is scheduled for 8:00 a.m. ET, on June 12, 2025, following the presentation of findings at a major hematology congress.

Webcast and Conference Call Details

Participants can expect a comprehensive discussion of the latest clinical trial data during this conference call. The access details for the live event are as follows:

Date and Time: Thursday, June 12, at 8:00 a.m. ET / 2:00 p.m. CEST

Access Instructions: Interested individuals can join the live webcast through the company's official investors' section on their website. For those wishing to participate via telephone, U.S. participants can dial 877-346-6112 and international participants can reach the call at 1-848-280-6350. A recording of the call and webcast will be available on Nurix's website for approximately 30 days for those who are unable to attend live.

Presentations at EHA2025

Nurix has valuable contributions to share at the European Hematology Association Congress, specifically regarding bexobrutideg (NX-5948). Here’s a summary of the key presentations:

Title: Bexobrutideg (NX-5948), a novel BTK degrader, shows promising clinical efficacy in relapsed refractory CLL
Presenting Author: Talha Munir M.B. Ch.B., Ph.D.
Session Title: Poster Session 1
Session Date: Friday, June 13 (18:30 - 19:30 CEST)
Abstract ID: PF571

Title: Bexobrutideg (NX-5948) demonstrates high clinical efficacy in Waldenström macroglobulinemia
Presenting Author: Dima El-Sharkawi, M.B., B.S., Ph.D.
Session Title: Poster Session 2
Session Date: Saturday, June 14 (18:30 - 19:30 CEST)
Abstract ID: PS1883

About Bexobrutideg (NX-5948)

Bexobrutideg is an innovative small molecule designed to degrade BTK and is currently under assessment in a Phase 1 clinical trial for patients suffering from relapsed or refractory B cell malignancies. This investigational treatment is notable for its oral bioavailability and ability to penetrate the brain, making it a promising candidate in oncology.

Learn More About Nurix Therapeutics

Nurix Therapeutics is at the forefront of drug design, focusing on developing medications that target protein degradation. Their approach is aimed primarily at enhancing therapies for patients battling cancer and inflammatory diseases. The company is advancing its pipeline that includes additional promising therapies such as BTK degraders and CBL-B inhibitors, underscoring their commitment to translating science and AI-driven discoveries into effective clinical solutions.

Frequently Asked Questions

What is nurix therapeutics focusing on?

Nurix Therapeutics is focused on discovering, developing, and commercializing targeted protein degradation medicines to enhance treatment options for various diseases.

When is the webcast scheduled?

The webcast conference call is scheduled for June 12, 2025, at 8:00 a.m. ET.

How can I access the webcast?

The webcast can be accessed on Nurix's official investor page on their website.

What are the objectives of the clinical trial for bexobrutideg?

The clinical trial aims to evaluate the safety and efficacy of bexobrutideg in treating patients with relapsed or refractory B cell malignancies.

Who can participate in the conference call?

Anyone interested may participate via the provided dial-in numbers or join through the webcast link available on the official website.

About The Author

Hey there I'm Caleb Price, a writer and financial specialist who loves to assist others in understanding the financial world. Having years of practical experience and a solid background in finance, my area of expertise is converting difficult financial ideas into useful, doable insights for my blog and publications. My goal with my writing is to give readers the information and assurance they need to successfully negotiate their financial journeys.

My ability to interact with a wide range of people—from novices starting their investing journey to seasoned investors looking for new approaches—has come from contributing to several financial blogs. Making money approachable and understandable is my goal; this will enable you to make wise choices and realize your financial objectives. We appreciate you coming along on this path to success and financial empowerment on Investors Hangout.

Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to [email protected].

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.